Eli Lilly stock gains as Foundayo data broaden obesity case

Eli Lilly reported positive Phase 3 results for Foundayo in obstructive sleep apnea on Monday, November 9, adding a potential indication to the company's expanding obesity portfolio. The release followed presentations at the American Heart Association Scientific Sessions and publication in JAMA. Lilly's announcement said the ATTAIN-OSA program met its primary endpoint after 52 weeks.

Foundayo expands its clinical reach

Among participants not using positive airway pressure therapy, Foundayo reduced apnea-hypopnea index events by 43.8 percent. In the group using the therapy, the reduction was 27.5 percent. The company also reported lower sleep-apnea-related oxygen burden and improvements in weight, inflammation and systolic blood pressure.

Lilly plans to submit Foundayo to the US Food and Drug Administration for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026. Regulatory approval is not assured, but an additional indication would give Lilly another route to expand the use of its once-daily oral GLP-1 medicine.

Commercial implications for Lilly

The results strengthen the case for an obesity franchise that extends beyond injectable tirzepatide products. They also add a potential growth avenue as Lilly develops Foundayo across several cardiometabolic conditions. Investors will focus next on the planned filing and on whether clinical progress translates into broader prescribing and reimbursement.

Eli Lilly stock traded at 1,268.50 euros on Lang & Schwarz at 16:40 CET on Tuesday, November 10, 1.64 percent above the Xetra close of Monday, November 9.

The S&P 500 market environment remains the relevant broader-market reference for US-listed shares.

More news and analyses on Eli Lilly stock